COMPARATIVE STUDY
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Antineoplastic Actions of Cinnamic Acids and Their Dimers in Breast Cancer Cells: A Comparative Study.

BACKGROUND/AIM: Breast cancer is the second leading cause of cancer-related deaths in US, which necessitates constant research for medications with minimal adverse effects. The aim of the study was to determine if certain cinnamic acid dimers (CADs) exhibit higher cytotoxicity in breast cancer cells than against non-tumorigenic cells.

MATERIALS AND METHODS: These dimers have not been explored, so far, due to their complex stereochemistry; cavitand-mediated photodimerization (CMP) method was used to produce several CADs, which were tested for cytotoxicity, apoptosis and cell cycle inhibition.

RESULTS: CADs such as ferulic acid dimer, 3-fluoro CAD, and 3, 4-difluoro CAD, were found to be more cytotoxic than their parent monomers. The most potent compound, 3-fluoro CAD caused apoptosis and 'S' phase cell cycle arrest in cancer cells.

CONCLUSION: This study indicates an avenue for research for developing a novel class of antineoplastic compounds that can be synthesized using an easy, economical method.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app